177 related articles for article (PubMed ID: 38039357)
1. EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors.
Li D; Guo X; Yang K; Yang Y; Zhou W; Huang Y; Liang X; Su J; Jiang L; Li J; Fu M; He H; Yang J; Shi H; Yang H; Tong A; Chen N; Hu J; Xu Q; Wei YQ; Wang W
Sci Adv; 2023 Dec; 9(48):eadg9721. PubMed ID: 38039357
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer.
Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W
Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795
[TBL] [Abstract][Full Text] [Related]
3. Chimeric Antigen receptor-T (CAR-T) cells targeting Epithelial cell adhesion molecule (EpCAM) can inhibit tumor growth in ovarian cancer mouse model.
Fu J; Shang Y; Qian Z; Hou J; Yan F; Liu G; Dehua L; Tian X
J Vet Med Sci; 2021 Mar; 83(2):241-247. PubMed ID: 33328392
[TBL] [Abstract][Full Text] [Related]
4. Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models.
Qin D; Li D; Zhang B; Chen Y; Liao X; Li X; Alexander PB; Wang Y; Li QJ
Oncoimmunology; 2020 Aug; 9(1):1806009. PubMed ID: 32923168
[TBL] [Abstract][Full Text] [Related]
5. Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses.
Yang Y; McCloskey JE; Yang H; Puc J; Alcaina Y; Vedvyas Y; Gomez Gallegos AA; Ortiz-Sánchez E; de Stanchina E; Min IM; von Hofe E; Jin MM
Cancer Immunol Res; 2021 Oct; 9(10):1158-1174. PubMed ID: 34341066
[TBL] [Abstract][Full Text] [Related]
6. Co-infusion of CAR T cells with aAPCs expressing chemokines and costimulatory ligands enhances the anti-tumor efficacy in mice.
Li J; Zhou W; Li D; Huang Y; Yang X; Jiang L; Hu X; Yang J; Fu M; Zhang M; Wang F; Li J; Zhang Y; Yang Y; Yan F; Gao H; Wang W
Cancer Lett; 2023 Aug; 568():216287. PubMed ID: 37392990
[TBL] [Abstract][Full Text] [Related]
7. Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells against solid tumor.
Gao G; Liao W; Shu P; Ma Q; He X; Zhang B; Qin D; Wang Y
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37591632
[TBL] [Abstract][Full Text] [Related]
8. Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models.
Zhang Q; Zhang H; Ding J; Liu H; Li H; Li H; Lu M; Miao Y; Li L; Zheng J
J Immunol Res; 2018; 2018():4263520. PubMed ID: 30410941
[TBL] [Abstract][Full Text] [Related]
9. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
Deng Z; Wu Y; Ma W; Zhang S; Zhang YQ
BMC Immunol; 2015 Jan; 16(1):1. PubMed ID: 25636521
[TBL] [Abstract][Full Text] [Related]
10. Inducible expression of interleukin-12 augments the efficacy of affinity-tuned chimeric antigen receptors in murine solid tumor models.
Yang Y; Yang H; Alcaina Y; Puc J; Birt A; Vedvyas Y; Gallagher M; Alla S; Riascos MC; McCloskey JE; Du K; Gonzalez-Valdivieso J; Min IM; de Stanchina E; Britz M; von Hofe E; Jin MM
Nat Commun; 2023 Apr; 14(1):2068. PubMed ID: 37045815
[TBL] [Abstract][Full Text] [Related]
11.
Xu T; Karschnia P; Cadilha BL; Dede S; Lorenz M; Seewaldt N; Nikolaishvili E; Müller K; Blobner J; Teske N; Herold JJ; Rejeski K; Langer S; Obeck H; Lorenzini T; Mulazzani M; Zhang W; Ishikawa-Ankerhold H; Buchholz VR; Subklewe M; Thon N; Straube A; Tonn JC; Kobold S; von Baumgarten L
Oncoimmunology; 2023; 12(1):2163781. PubMed ID: 36687005
[TBL] [Abstract][Full Text] [Related]
12. Construction of chimeric antigen receptor‑modified T cells targeting EpCAM and assessment of their anti‑tumor effect on cancer cells.
Zhou Y; Wen P; Li M; Li Y; Li XA
Mol Med Rep; 2019 Sep; 20(3):2355-2364. PubMed ID: 31322180
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin Pretreatment Rescues the Bone Marrow AML Cell Elimination Capacity of CAR-T Cells.
Nian Z; Zheng X; Dou Y; Du X; Zhou L; Fu B; Sun R; Tian Z; Wei H
Clin Cancer Res; 2021 Nov; 27(21):6026-6038. PubMed ID: 34233960
[TBL] [Abstract][Full Text] [Related]
14. Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report.
Sun H; Xing C; Jiang S; Yu K; Dai S; Kong H; Jin Y; Shan Y; Yang W; Wang Z; Xiao J; Wang H; Wang W; Li Z; Shi K
Front Immunol; 2022; 13():963031. PubMed ID: 36059488
[TBL] [Abstract][Full Text] [Related]
15. [Humanized BCMA CAR-T cell salvage therapy in two refractory multiple myeloma patients who progressed after their murine BCMA CAR-T cell therapy].
Cui R; Li P; Li Q; Mu J; Jiang YL; Jiang YY; Deng Q
Zhonghua Xue Ye Xue Za Zhi; 2021 Jun; 42(6):502-507. PubMed ID: 34384157
[No Abstract] [Full Text] [Related]
16. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
Stock S; Benmebarek MR; Kluever AK; Darowski D; Jost C; Stubenrauch KG; Benz J; Freimoser-Grundschober A; Moessner E; Umana P; Subklewe M; Endres S; Klein C; Kobold S
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902133
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor-T Cell Therapy Decreases Distant Metastasis and Inhibits Local Recurrence Post-surgery in Mice.
Li D; Jiang L; Zhou W; Huang Y; Yang Y; Li J; Yang J; Wang F; Li J; Zhang Y; Yan F; Gao H; Guo X; Xu Q; Tan S; Wei YQ; Wang W
Hum Gene Ther; 2023 Dec; 34(23-24):1248-1256. PubMed ID: 37917093
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy.
Chiriaco C; Donini C; Cortese M; Ughetto S; Modica C; Martinelli I; Proment A; Vitali L; Fontani L; Casucci M; Comoglio PM; Giordano S; Sangiolo D; Leuci V; Vigna E
J Exp Clin Cancer Res; 2022 Oct; 41(1):309. PubMed ID: 36271379
[TBL] [Abstract][Full Text] [Related]
19. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
Majzner RG; Theruvath JL; Nellan A; Heitzeneder S; Cui Y; Mount CW; Rietberg SP; Linde MH; Xu P; Rota C; Sotillo E; Labanieh L; Lee DW; Orentas RJ; Dimitrov DS; Zhu Z; Croix BS; Delaidelli A; Sekunova A; Bonvini E; Mitra SS; Quezado MM; Majeti R; Monje M; Sorensen PHB; Maris JM; Mackall CL
Clin Cancer Res; 2019 Apr; 25(8):2560-2574. PubMed ID: 30655315
[TBL] [Abstract][Full Text] [Related]
20. Effective Targeting of TAG72
Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
Front Immunol; 2018; 9():2268. PubMed ID: 30510550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
